Description: NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Home Page: www.nervgen.com
112-970 Burrard Street
Vancouver,
BC
V6Z 2R4
Canada
Phone:
778 731 1711
Officers
| Name | Title |
|---|---|
| Mr. Michael Kelly | CEO, President & Director |
| Mr. William Joseph Radvak BASc | Co-Founder & Advisor |
| Dr. Harold Martin Punnett D.M.D. | Co-Founder & Independent Director |
| Mr. William J. Adams C.A., CPA, CA, CPA | CFO & Corporate Secretary |
| Dr. Daniel D. Mikol M.D., Ph.D. | Chief Medical Officer |
| Mr. Brian McAlister | Co-Founder & Advisor |
| Dr. Charles V. Olson D.Sc. | Senior Vice President of Technical Operations |
| Ms. Elizabeth Eberhardt B.Sc. | Senior Vice President of Program Management |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 20.4675 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |